ASGCT 2026: Ascidian Therapeutics is presenting initial human safety data from its RNA exon editing platform in a Stargardt disease trial
- 31 minutes ago
- 1 min read
CSO Robert Bell describes the advantages of RNA exon editing he sees over DNA editing, and walks us through the safety data. With that in hand, which was in adult patients, the company is moving forward in pediatric patients.
Coverage brought to you by







.png)
